RedChip Interviews Aridis Pharmaceuticals’ CEO Vu Truong

ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Corporations will air a brand new C-Stage interview with Aridis Prescription drugs (NASDAQ:ARDS) on The RedChip Cash Report® on Bloomberg TV, this Saturday, July 2, at 7 p.m. Japanese Time (ET). Bloomberg TV is out there in an estimated 73 million properties throughout the U.S.

RedChip’s TV Host Craig Brelsford interviews Aridis’ CEO Vu Truong on this unique interview, protecting the questions on the thoughts of present and future shareholders.

Entry this interview in its entirety at https://www.aridispharmainfo.com/interview_access

The Firm’s proprietary expertise platforms, ʎPEX and MabIgX®, can quickly determine human-derived monoclonal antibodies for numerous infectious ailments and apply them in a brand-new means as therapeutic brokers that optimally neutralize invading pathogens. Developed by a world-class workforce of scientists, ARDS’ strategy to treating infectious ailments utilizing the affected person’s personal immune system to determine monoclonal antibodies that may struggle infections, may end in a therapy paradigm shift. With knowledge for its section 3 scientific trial for acute pneumonia anticipated within the 2H2022, and section 2a knowledge additionally anticipated within the 1H2022 for Cystic Fibrosis sufferers, there are a number of near-term catalysts that might end in important inventory worth appreciation. Medical knowledge from the Firm’s revolutionary COVID mAb program can also be anticipated in 2H2022. 5 analysts cowl the inventory with worth targets starting from $11-$22, considerably above latest costs. Aridis’ world-class workforce of senior executives, with expertise in bringing multi-billion-dollar drug candidates to market, ought to give traders’ confidence within the Firm’s capacity to execute on its enterprise technique.

Interview highlights:

Within the unique RedChip Cash Report interview, Truong discusses near-term knowledge, the Part 2a trial being funded by the Cystic Fibrosis Basis, potential gross sales expectations, and far more.

Entry this interview in its entirety at https://www.aridispharmainfo.com/interview_access

About The RedChip Cash Report®

The RedChip Cash Report® is produced by RedChip Corporations Inc., a world Investor Relations and media agency with 30 years’ expertise centered on Discovering Tomorrow’s Blue Chips Right this moment™. “The RedChip Cash Report®” delivers insightful commentary on small-cap investing, interviews with Wall Avenue analysts, monetary guide evaluations, in addition to featured interviews with executives of public corporations.

About Aridis Prescription drugs

Aridis Prescription drugs, Inc. discovers and develops anti-infectives for use as first-line remedies to fight antimicrobial resistance (AMR) and viral pandemics. The Firm is using its proprietary ʎPEX and MabIgX® expertise platforms to quickly determine uncommon, potent antibody-producing B-cells from sufferers who’ve efficiently overcome an an infection, and to quickly manufacture mAbs for therapeutic therapy of vital infections. These mAbs are already of human origin and functionally optimized by the pure human immune system for top efficiency. Therefore, they’re already fit-for-purpose and don’t require additional engineering optimization to realize full performance.

The Firm has generated a number of scientific stage mAbs concentrating on micro organism that trigger life-threatening infections comparable to ventilator related pneumonia (VAP) and hospital acquired pneumonia (HAP), along with preclinical stage antibacterial and antiviral mAbs. The usage of mAbs as anti-infective remedies represents an revolutionary therapeutic strategy that harnesses the human immune system to struggle infections and is designed to beat the deficiencies related to the present customary of care, which is broad spectrum antibiotics. Such deficiencies embody, however are usually not restricted to, rising drug resistance, quick period of efficacy, disruption of the conventional flora of the human microbiome and lack of differentiation amongst present remedies. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to deal with lung infections in cystic fibrosis sufferers.

About RedChip Corporations

RedChip Corporations, an Inc. 5000 firm, is a world investor relations, media, and analysis agency centered on microcap and small-cap corporations. For 30 years, RedChip has delivered concrete, measurable outcomes for its purchasers. Our e-newsletter, the RedChip Cash Report is delivered on-line weekly to 60,000 traders. RedChip has developed essentially the most complete service platform within the trade for microcap and small-cap corporations. These providers embody the next: a worldwide distribution community for its inventory analysis; retail and institutional roadshows in main U.S. cities; outbound advertising to inventory brokers, RIAs, establishments, and household places of work; a digital media investor relations platform that has generated hundreds of thousands of distinctive investor views; investor webinars and group calls; a tv present, “The RedChip Cash Report,” which airs weekly on Bloomberg US; TV commercials in native and nationwide markets; company and product movies; web site design; and conventional investor relation providers, which embody press launch writing, improvement of investor displays, quarterly convention name script writing, strategic consulting, capital elevating, and extra.

To be taught extra about RedChip’s services, please go to:

https://www.redchip.com/company/investor_relations

“Discovering Tomorrow’s Blue Chips Right this moment”™

Ahead Trying Statements

Sure statements on this press launch are forward-looking statements that contain various dangers and uncertainties. These statements could also be recognized by means of phrases comparable to “anticipate,” “consider,” “forecast,” “estimated” and “intend” or different comparable phrases or expressions that concern Aridis’ expectations, technique, plans or intentions. These forward-looking statements are based mostly on Aridis’ present expectations and precise outcomes may differ materially. There are a variety of things that might trigger precise occasions to vary materially from these indicated by such forward-looking statements. These components embody, however are usually not restricted to, the necessity for added financing, the timing of regulatory submissions, Aridis’ capacity to acquire and preserve regulatory approval of its present product candidates and every other product candidates it could develop, approvals for scientific trials could also be delayed or withheld by regulatory businesses, dangers referring to the timing and prices of scientific trials, dangers related to acquiring funding from third events, administration and worker operations and execution dangers, lack of key personnel, competitors, dangers associated to market acceptance of merchandise, mental property dangers, dangers associated to enterprise interruptions, together with the outbreak of COVID-19 coronavirus, which may severely hurt our monetary situation and improve our prices and bills, dangers related to the uncertainty of future monetary outcomes, Aridis’ capacity to draw collaborators and companions and dangers related to Aridis’ reliance on third get together organizations. Whereas the record of things offered right here is taken into account consultant, no such record ought to be thought-about to be an entire assertion of all potential dangers and uncertainties. Unlisted components could current important further obstacles to the conclusion of forward-looking statements. Precise outcomes may differ materially from these described or implied by such forward-looking statements on account of numerous necessary components, together with, with out limitation, market situations and the components described beneath the caption “Threat Elements” in Aridis’ 10-Okay for the yr ended December 31, 2021, and Aridis’ different filings made with the Securities and Change Fee. Ahead-looking statements included herein are made as of the date hereof, and Aridis doesn’t undertake any obligation to replace publicly such statements to mirror subsequent occasions or circumstances.

Contact:

Dave Gentry
RedChip Corporations Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
[email protected]

–END–

SOURCE: RedChip

View supply model on accesswire.com:
https://www.accesswire.com/707177/RedChip-Interviews-Aridis-Prescription drugs-CEO-Vu-Truong